New drug combo aims to stall endometrial cancer

NCT ID NCT07684599

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new combination or usual care. The study measures how long participants live without their cancer worsening and checks for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK5733584 (an experimental drug) combined with immunotherapy (dostarlimab or pembrolizumab)
What this could lead to: If successful, this combination could become a new maintenance therapy to delay cancer progression in people with advanced endometrial cancer.
What could go wrong: This is an early-phase study, so the experimental drug may not improve outcomes or could cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, ENDOMETRIAL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.